No AAV? No prob­lem. Code Bio­ther­a­peu­tics joins the search for a non-vi­ral gene ther­a­py

Bri­an McVeigh’s wake-up call came one morn­ing in the form of a LinkedIn no­ti­fi­ca­tion con­grat­u­lat­ing him for 25 years at Glax­o­SmithK­line.

“I was like, ‘Oh my God, it has been a quar­ter cen­tu­ry at one com­pa­ny, what am I do­ing?’” he said.

McVeigh quit his job as VP of world­wide busi­ness de­vel­op­ment trans­ac­tions and in­vest­ment man­age­ment in No­vem­ber 2017, spent half a year as the CEO of KBP Bio­Sciences, and even­tu­al­ly end­ed up on the board of Geni­sphere, where sci­en­tists were work­ing on a drug de­liv­ery plat­form us­ing syn­thet­ic DNA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER